Development of new strategies of human antitumor dendritic cell vaccines

Informations projet

MYRTO-GEORDIA TRAKAT

N° de convention de subvention: QLK2-CT-1999-51390

Projet clôturé

Date de début 1 Août 2000

Date de fin 31 Juillet 2002

Financé au titre de

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Coût total € 159 400,00

Contribution de l’UE € 159 400,00

Coordonné par

UNIVERSITE LIBRE DE BRUXELLES
Belgium

Objectif

The project aims to investigate in healthy donors and in melanoma patients, strategies that could improve the generation of MAGE-specific antitumor cytotoxic immune responses by vaccination with autologous dendritic cells.

Champ scientifique

• medical and health sciences › clinical medicine › oncology › skin cancer › melanoma
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thème(s)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Appel à propositions

Data not available

Régime de financement

RGI - Research grants (individual fellowships)

Coordinateur

UNIVERSITE LIBRE DE BRUXELLES

• Contribution de l’UE: Aucune donnée
• Adresse: Route de Lennik 808 ; 1070 BRUXELLES ; Belgique
• Coût total: Aucune donnée